Researchers studied a cohort of patients admitted between Jan. 1, 2006, and Oct. 1, 2015, to St. Louis-based Barnes-Jewish Hospital. They identified patients with multidrug-resistant organisms obtained from the bloodstream, bronchoalveolar lavage and bronchial wash or other sterile sites. They examined all readmissions within one year of the patient’s initial hospitalization for multidrug-resistant infections. They evaluated bloodstream, BAL and bronchial wash or other sterile site cultures positive for the same or different organisms.
Of 4,429 unique patients with a positive culture for a multidrug-resistant organism, 78 percent survived the initial hospitalization. Researchers found that 61.6 percent were readmitted at least one time within a year, for a total of 5,849 readmissions. Additionally, 24.1 percent of patients had the same or a different multidrug-resistant organism isolated from blood, BAL and bronchial wash or another sterile site during a readmission.
The following factors during index hospitalization were associated with increased risk of having a multidrug-resistant isolated during a readmission:
• Bone marrow transplant
• End-stage renal disease
• Lymphoma
• Methicillin-resistant Staphylococcus aureus
• Carbapenem-resistant Pseudomonas aeruginosa
More articles on healthcare quality:
Study: Antiviral drugs may permit the safe transplant of hepatitis C-positive livers
Flu shot now recommended for people with egg allergies: 3 things to know
More than 300 sickened with gastro illness on Royal Caribbean cruise ship
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.